OrthoPediatrics (KIDS) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• OrthoPediatrics (KIDS) is set to announce its Q2 2025 earnings on August 5th, with analysts predicting a loss of $0.17 per share and revenue of $61.40 million.
• In the previous quarter, the company reported a loss of $0.39 per share, missing estimates, while revenue beat expectations at $52.41 million.
• OrthoPediatrics currently holds a market capitalization of $543.85 million, and analysts maintain a consensus rating of "Moderate Buy" with an average price target of $35.83.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) is expected to announce its Q2 2025 earnings results after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $61.40 million for the quarter. OrthoPediatrics has set its FY 2025 guidance at EPS.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). The company had revenue of $52.41 million during the quarter, compared to analyst estimates of $51.68 million. OrthoPediatrics had a negative net margin of 19.15% and a negative return on equity of 7.03%. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Stock Performance

Shares of OrthoPediatrics stock opened at $22.39 on Tuesday. The company has a market capitalization of $543.85 million, a PE ratio of -12.79 and a beta of 1.10. OrthoPediatrics has a 12 month low of $19.51 and a 12 month high of $33.16. The company has a current ratio of 6.19, a quick ratio of 2.99 and a debt-to-equity ratio of 0.21. The stock's fifty day simple moving average is $21.54 and its 200 day simple moving average is $22.96.

Analyst Ratings Changes

KIDS has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 price objective on shares of OrthoPediatrics in a research note on Thursday, May 8th. Lake Street Capital initiated coverage on OrthoPediatrics in a research note on Monday, April 7th. They set a "buy" rating and a $37.00 price objective on the stock. Truist Financial dropped their price objective on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. BTIG Research reaffirmed a "buy" rating on shares of OrthoPediatrics in a research note on Monday, July 14th. Finally, Wall Street Zen downgraded OrthoPediatrics from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $35.83.

Institutional Trading of OrthoPediatrics

Several hedge funds and other institutional investors have recently modified their holdings of KIDS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company's stock valued at $246,000 after acquiring an additional 645 shares in the last quarter. Millennium Management LLC grew its holdings in shares of OrthoPediatrics by 55.3% in the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company's stock valued at $16,172,000 after acquiring an additional 233,873 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of OrthoPediatrics by 112.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company's stock valued at $4,937,000 after acquiring an additional 106,041 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of OrthoPediatrics in the 1st quarter valued at about $389,000. Institutional investors and hedge funds own 69.05% of the company's stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.